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| INTRODUC TI ON
Gallbladder cancer (GBC) is the sixth most common type of digestive tract carcinoma and the most common type of biliary cancer but is still a relatively infrequent malignancy, with a morbidity rate of 1/100,000-23/100,000. 1, 2 However, the incidence of GBC has steadily risen at the rate of 4% in the past 10 years. 3 GBC is also a highly lethal disease, with a 5-year survival rate of 5%-10%.
Complete surgical resection is the only curative therapy for GBC 4 , with only 10% of GBC patients (with early-stage disease) having the opportunity to receive complete surgical resection. 5 Therefore, chemotherapy is critical for GBC patients. Gemcitabine-based chemotherapy is the first-line treatment for advanced GBC patients in the National Comprehensive Cancer Network (NCCN) Guidelines. 6, 7 Nevertheless, some studies report the negative impacts of gemcitabine-based chemotherapy and potential shorter survival of GBC patients. 8 The precise mechanism is unknown at present, but a practical risk stratification model for GBC to predict the prognosis after surgical resection and the benefit from gemcitabine-based chemotherapy is urgently needed.
The most widely used model for GBC is the TNM staging system published by the American Joint Committee on Cancer (AJCC). The TNM staging system classifies GBC patients by the extent and size of the primary tumor (T), the involvement of regional lymph nodes (N), and the absence or presence of distant metastases (M). 9 Although the TNM staging system has been validated and accepted worldwide, heterogeneous prognosis still exists for each stage. With the increasing knowledge of the tumor microenvironment (TME) and the rapid development of tumor immunology, the crucial role of tumor-infiltrating immune cells in the TME is becoming clearer, improving the predictive efficiency of the TNM staging system.
As an essential hallmark of cancer, inflammation is the most common risk factor of GBC, which primarily presents as a gallbladder stone. 1, 2, 10, 11 Inflammation inside tumors is induced by tumor-infiltrating immune cells, which constitute the TME together with tumor-associated fibroblasts (TAF) and vascular endothelial cells (VEC). [12] [13] [14] The tumor-infiltrating immune cells in the TME mainly include lymphoid lineage cells such as T cells and B-cells, and myeloid lineage cells such as macrophages, neutrophils and mast cells (MC). [12] [13] [14] These immune cells could communicate with each other and play a promotive or contrary function on the initiation, growth and invasion of tumor cells, directly or indirectly. [15] [16] [17] [18] [19] Furthermore, some research suggests that the immune elements in TME could modulate chemotherapy response. [20] [21] [22] In consideration of the important value of tumor-infiltrating immune cells, we evaluated the different kinds of immune cells, constructed an immune index model using multiple linear regression and explored its prognostic value for clinical outcomes, especially for gemcitabine-based chemotherapy. Our work illustrates the importance of tumor-infiltrating immune cells and develops a promising system to predict prognosis and chemotherapy benefit in GBC.
| PATIENTS AND ME THODS

| Study design
The flow chart of the study is shown in Figure 1 . This study was approved by the Institutional Review Board (IRB) of Fudan University Zhongshan Hospital and informed consent was obtained from each patient. A total of 238 consecutive patients with GBC undergoing radical resection or palliative surgery were enrolled in our study from Fudan University Zhongshan Hospital in 
| Immunohistochemistry and evaluation of immune cells
| Least Absolute Shrinkage and Selection Operator
Least absolute shrinkage and selection operator (LASSO) is a co-regression analysis method that can reduce the dimension of original data and produce a statistical model. It performs both variable selection and regularization and enhances the prediction accuracy and interpretability of the statistical model. Because LASSO regression has a low requirement for original data, it has been applied in many medical modeling processes. [24] [25] [26] [27] We adopted LASSO regression to construct the prognostic model in our study. 
| Statistical analyses
| RE SULTS
| Characteristics of immune cells
Tumor-infiltrating immune cells were assessed by immunohistochemical staining of specific polyclonal antibodies ( Figure 2A ). As shown in Figure 2B We also explored the relationship between TNM stage and tumor-infiltrating immune cells. As shown in Figure S2 , there was no difference between stages I-II and stages III-IV for the infiltration of macrophages, Tregs, CTL and mast cells (but there was a difference for neutrophils). Cell counts of infiltrating neutrophils in stages III-IV were significantly higher than those in stages I-II (P < 0.001).
Immune cells are not isolated from each other. As presented in Figure S3 , significant Spearman's rank correlation coefficients occurred between immune cells. There were significant positive correlations between macrophages, neutrophils and Tregs, and between CTL and mast cells. A significant negative correlation also existed between neutrophils and mast cells.
| Construction of immune index model
To explore the predictive ability of the different immune cells, we divided the patients into high or low infiltration on the basis of median counts of tumor-infiltrating immune cells and conducted survival analysis. As shown in Figure S4 , high infiltration of macrophages, neutrophils and Tregs predicted compromised prognosis (P < 0.001, P < 0.001, P = 0.011, respectively), while high infiltration of CTL and mast cells predicted favorable prognosis (P = 0.002 and P = 0.008, respectively). (Table S1 ).
| Correlation between immunotype and overall survival
To investigate the difference between immunotype A and immunotype B, we constructed a heat map according to the immune index, from low to high. As shown in Figure 3A , with the increase of the immune index and the conversion of immunotype, the main tumorinfiltrating immune cells gradually changed from CTL and mast cells to macrophages, neutrophils and Tregs in the training set. The validation set had the same trend. Following this, we assessed the influence of the immune index on patients' prognosis using smooth hazard ratio (HR) curves of OS. As shown in Figure 3B , the Ln (HR) increased obviously with the gradual increase of the immune index in both sets. The HR and 95% confidence interval (CI) for both sets were 3.081(2.040-4.654), P < 0.001 and 2.207(1.361-3.581), P = 0.001, respectively.
As shown in Figure 3A , the 5-year OS of immunotype A vs immunotype B in both sets were 70.0% vs 37.0% and 68.9% vs 47.5%, respectively. To further verify the predictive value of the immune index model, we compared the OS based on immunotypes using survival curves. Immunotype B patients demonstrated a more lower OS than immunotype A patients in the training set ( Figure 3C , P = 0.002). The results were similar for the validation set ( Figure 3C , P < 0.001). We also conducted a subgroup analysis of OS according to immunotype in the combined set, and found that immunotype was an effective prognostic predictor for OS in all the subgroups ( Figure S5 ).
Univariate and multivariate analysis was performed to further verify the clinical value of the immune index model. Immunotype proved to be an effective predictive factor in both sets (P = 0.001 and P = 0.004, respectively; Table 2 ). Subsequently, all the statistically respectively) were still independent prognostic indicators for OS in both sets (Table 2 ). Figure 3D ). All the results were similar in the validation set.
| Efficiencies of prognostic models
Accordingly, we found that our immune index model was more effective than any single immune cell model and might improve on the TNM staging system.
| Correlation between immunotype and chemotherapy
We evaluated the association between immunotype and gemcitabine-based chemotherapy, which was widely used in gallbladder cancer patients with stage II-IV disease. As shown in Figure 4A respectively) ( Figure 4C ).
We conduct a subgroup analysis to further explore the influence of immunotype on chemotherapy. As shown in Figure 4D 
| D ISCUSS I ON
In this study, we integrated five tumor-infiltrating immune cells in GBC tissue, which we selected based on literature review, and constructed the immune index model using LASSO regression.
Our model could effectively predict the prognosis and the gemcit- Figure S6 ). Compared with single immune cell models, our integrated model had a more precise prediction efficiency, and could elevate the discriminatory power of the TNM staging system.
Applying an "immunoscore," that is, using immunostaining of CD3 + cells and CD8 + cells, was first proposed by Galon. 28 Based on the adaptive immune response, the immunoscore model proved to be a strong prognostic factor for survival of colon cancer in a multi-center clinical trial. 29 Galon also suggested that additional markers could be added subsequently to refine the method even further. 30, 31 Thanks to the great effort of scientists, the important roles of innate immune and myeloid-derived cells were discovered recently. [32] [33] [34] [35] [36] [37] [38] [39] [40] However, an effective model for GBC based on both adaptive immune cells and innate immune cells, both lymphoid-derived cells and myeloid-derived cells, and both pro-tumor cells and anti-tumor cells, is urgently needed.
Our immune index model for GBC was constructed with this background. Compared with Galon's immunoscore model, our and is constructed with a more complicated formula, so that it is more comprehensive and can reflect the TME more precisely, although the complicated formula might be a hinderance for widespread clinical application.
In our immune index model, macrophages, neutrophils and Tregs were negative predictors while CTL and mast cells were positive predictors. This result is in accord with previous literature. CTL are the main effector cells in TME, which can induce tumor cell apoptosis by expressing FasL or secreting perforin, granzyme or IFN-γ. 15 Mast cells have been reported to activate CTL by releasing TNF-α and OX40L, 41, 42 while Tregs can directly inhibit the killing function of CTL in a cell-cell contact-dependent manner. [43] [44] [45] Macrophages can inhibit the effector function of CTL directly through secretion of PD-L1, IL-10, TGF-β or ROS, or indirectly by recruiting Tregs or inhibiting the recruitment and recognition of CTL. [46] [47] [48] [49] Neutrophils can secrete ROS, RNS and neutrophil elastase (NE), IL-1RA, ARG-1 to promote tumor initiation and tumor growth. [50] [51] [52] The role of these immune cells in TME and their different distribution in patients might be the reason why GBC patients with same stage had totally different prognoses.
Interestingly, we found positive correlations between the poor predictors (macrophages, neutrophils and Tregs) and between the favorable predictors (CTL and mast cells). There was also a negative correlation between mast cells and neutrophils. The driving factor of this result was hard to determine in our study, but it proved that the immune cells in the TME did not exist independently.
Correspondingly, these immune cells might keep communicating
with each other through direct contact or various cytokines, as mentioned above. 41, [43] [44] [45] [46] [47] [48] [49] [50] [51] The gemcitabine-based chemotherapy has been proved to prolong the survival time of advanced GBC patients and has remained the first-line regimen since 2004. [53] [54] [55] However, there is conflicting evidence regarding the role of gemcitabine for GBC. In a randomized controlled trial, Edeline (2019) reported that the gemcitabine-based treatment not only did not bring a survival benefit for GBC but might even promote tumor recurrence and shorten patients' survival. 8 and elevated CD8 density after chemoradiotherapy was associated with a favorable clinical outcome. 55 While the effect of chemotherapy on the elevation of CD8 density might be rather weak for the immunotype A (CTL high ) patients in stage II, insufficient benefit but more side effects might be the possible reasons for the worse prognosis of immunotype A patients who received chemotherapy in stage II compared to patients without chemotherapy. This result is helpful for the clinical decision of who should receive gemcitabine-based chemotherapy, and for the prevention of excessive toxicity and unnecessary resource consumption. However, we also noticed that the 5-year OS of immunotype B patients receiving effective chemotherapy was still lower compared with immunotype A patients who benefit from gemcitabine-based chemotherapy. Therefore, new treatment options for them, such as effective targeted therapy and immunotherapy, are urgently needed.
The present study has some limitations. First, this study is a single-center and retrospective study with a relatively small number of patients. Therefore, more prospective studies or multi-center studies are needed to verify our results. Second, this study only included five immune cells, and some other immune cells that could affect patients' prognosis might be missed because of the lack of single and specific markers. We will update our model with further development of cell identification methods in the future.
In conclusion, we constructed a new immune index model of GBC by integrating multiple tumor-infiltrating immune cells. Our immune index model is practical for predicting the prognosis of GBC patients and might improve on the current TNM staging system. Furthermore, our data suggest that the immune index model might be useful for determining which patients are most likely to benefit from gemcitabine-based chemotherapy.
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